Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical industry, indicating a positive outlook for the sector compared to the overall market performance [2][22]. Core Insights - The pharmaceutical sector saw a weekly increase of 1.8%, outperforming the Shanghai Composite Index, which rose by 1.4% [3][5]. - The overall valuation of the pharmaceutical sector is at 24.0 times PE for 2025E, ranking 6th among 31 primary industries [5][8]. - Key events include the introduction of a new childcare subsidy policy in Hohhot, which may positively impact related pharmaceutical companies [10]. - The National Medical Insurance Administration has initiated pricing projects for neurological services, specifically for brain-computer interface technologies, which could create new market opportunities [10]. - A significant approval was granted to Kolun Pharmaceutical's TROP2 ADC for lung cancer treatment, marking a milestone in the industry [11]. Summary by Sections Market Performance - The pharmaceutical index increased by 1.8%, ranking 15th among 31 sub-industries [3][5]. - Various sub-sectors showed different performance levels, with offline pharmacies leading at +10.4% [5][6]. Key Events - Hohhot's childcare subsidy includes a one-time payment of 10,000 yuan for the first child and 50,000 yuan for the second child, potentially boosting the market for related pharmaceutical companies [10]. - The National Medical Insurance Administration's new pricing guidelines for neurological services include specific provisions for brain-computer interface technologies [10]. Company Highlights - Kolun Pharmaceutical's TROP2 ADC received approval for a new indication in lung cancer, which is expected to significantly benefit patient survival rates [11]. - The report suggests monitoring companies involved in childcare-related pharmaceuticals and those collaborating with Huawei in the medical field [10].

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is under pressure in 2024, with performance still in a bottoming process. The short-term landscape shows a high proportion of Me-too pipelines, leading to intense competition among similar products. Companies are facing a challenging environment and are actively adjusting their pipeline strategies to focus on high-barrier, well-competitive multi-valent products. The continuous integration of AI technology is expected to gradually empower vaccine research and development. Based on three driving factors—policy, demand, and technology—the long-term outlook for the vaccine industry remains positive, maintaining the "Overweight" rating [10][31][32]. Market Performance - Last week, the vaccine sector rose by 0.67%, which is relatively modest compared to other segments. The overall pharmaceutical and biological sector reported a 1.06% increase, while the vaccine sector has seen a cumulative decline of 5.66% since the beginning of 2025 [4][5][10]. Valuation Metrics - The vaccine sector's PE (ttm) was 34.02X, up by 0.23X week-on-week, with a one-year maximum of 41.43X and a minimum of 19.57X. The PB (lf) was 1.88X, also up by 0.01X week-on-week, with a one-year maximum of 2.91X and a minimum of 1.62X. The PE is at the 15.83% percentile and the PB at the 2.08% percentile over the past decade. The valuation premium of the vaccine sector relative to the CSI 300 is 169.54% [6][10][21]. Industry Dynamics and Company Announcements - Key developments include: 1. Kanglaisheng reported a 50.24% decline in revenue for 2024, with a total profit loss of 3.52 billion yuan, primarily due to increased R&D and depreciation costs [7][28]. 2. The company’s nine-valent HPV vaccine has completed the first analysis of its Phase III clinical trial, meeting the statistical criteria for efficacy [28]. 3. Kangtai Biotech received a summary report for its adsorbed tetanus vaccine's Phase I/III clinical trial, indicating good safety and immunogenicity [28]. 4. CloudTop's new mRNA personalized tumor therapeutic vaccine EVM16 has completed its first patient dosing, marking a significant step in AI-driven vaccine development [10][28].

根据 Counterpoint Research 的 《全球智能眼镜型号出货量追踪报告》 ，2024 年全球智能眼镜出货量 同比增长 210% ，主要受到 Ray-Ban Meta 智能眼镜强劲需求的推动。因此，全球智能眼镜市场首次 突破 200 万台大关，创下了前所未有的增长速度。 2024 年与 2023 年全球智能眼镜 市场出货量对比 在Ray-Ban Meta 智能眼镜的强劲需求推动下，2024 年全球智能眼镜出货量同比大幅增长 210%，2023 年则同比增长了 156%。 Ray-Ban Meta 智能眼镜通过将可穿戴 AI 技术与时尚设计和增强的智能功能相结合，重新定义 了智能眼镜体验。 在 Ray-Ban Meta 智能眼镜成功之后，像小米、三星、百度和字节跳动等科技巨头将加入全球 智能眼镜市场。供应链预计 2025 年将成为"智能眼镜百家争鸣"的时代。 我们预计全球智能眼镜市场将持续增长，2025 年同比增长 60% ，并且到 2029 年将保持超过 60% 的年均增长率，受益于更广泛的应用场景、多样化的价格段和不断扩展的玩家生态系 统。 来源：2025 年 1 月Counterpoint ...

《2025年国务院政府工作报告》（简称"政府工作报告"）出炉，明确2025年发展蓝图。 政府工作报告提到，要"因地制宜发展新质生产力，加快建设现代化产业体系"，要"培育壮大新兴产业、未来产业""推动传统产业改造提升""激发数字经济创 新活力"。在需求侧，要"大力提振消费、提高投资效益，全方位扩大国内需求""推动更多资金资源'投资于人'、服务于民生"。 上市公司是新质生产力发展和服务民生的重要微观主体，记者了解到，政府工作报告提出的关于发展新质生产力、推进高水平科技自立自强等内容引起沪市 代表委员的广泛关注。 发挥科技领军企业龙头作用 政府工作报告提出，"推进高水平科技自立自强。充分发挥新型举国体制优势，强化关键核心技术攻关和前沿性、颠覆性技术研发，加快组织实施和超前布局 重大科技项目""发挥科技领军企业龙头作用，加强企业主导的产学研深度融合，从制度上保障企业参与国家科技创新决策、承担重大科技项目""健全创投基 金差异化监管制度，强化政策性金融支持，加快发展创业投资、壮大耐心资本"等。 在推进高水平科技自立自强的进程中，上市公司扮演着科技创新主力军的作用。近年来，上市公司通过主导产学研融合、承担重大科技项目等方 ...

Financial Performance - Total revenue for 2024 reached ¥846,338,072.24, a year-on-year increase of 137.01%[4] - Net loss attributable to shareholders decreased to ¥378,884,001.37, a reduction of 74.45% compared to the previous year[6] - The company reported a significant reduction in operating losses by 80.62% and total losses by 80.74%[9] - The basic earnings per share improved to -¥1.53, compared to -¥6.01 in the previous year[4] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,958,132,235.38, a decrease of 14.60% year-on-year[4] Research and Development - Research and development expenses decreased significantly, contributing to improved operational efficiency[7] - The company focused on commercializing the ACYW135 meningococcal polysaccharide conjugate vaccine, which is the only four-valent meningococcal vaccine in the Chinese market[6] Operational Efficiency - The company optimized resource allocation and implemented cost-reduction measures, leading to a notable decrease in asset impairment losses[7] - The sales channel for the meningococcal vaccine was continuously developed, resulting in increased market penetration and sales volume[9] Risk Management - The company emphasizes the importance of monitoring investment risks as the financial data is preliminary and unaudited[10]

证 券 研 究 报 告 行业周报 AI为健康产业持续赋能 医药行业周报 | 投资评级： | 推荐 （ 维持 ） | | --- | --- | | 报告日期： | 2025年02月17日 | 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 1 . AI为健康产业持续赋能，接入DeepSeek有望加速普及 从病理图像智能识别到目前多模态医学大模型，AI持续为医疗健康产业赋能，并逐步重塑医疗诊断的模式。AI在医疗中的 应用首先体现在效率的提升和成本的节省，如智能阅片、自动生产电子病例，自动生成体检报告，将医生从重复性工作中 解放更专注于患者的治疗。2025年2月13日华为数据储存官宣，将于2月18日发布基于DCS AI解决方案的瑞金病理大模型， 多模态的医学大模型陆续发布，将头部医疗资源的诊疗经验以AI的方式向医疗系统推广，将提升整体的医疗资源，实现高 水平医疗诊断的广泛普及。整合AI的智能体还将医疗服务延伸至家庭端，如AI+CGM 不仅能持续监测血糖，还可以根据分 析数据以提供个性化的提示和建议。自国内原生的大模型Dee ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年2月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Financial Projections - The company expects to achieve an operating revenue of between 825 million and 865 million CNY for the year 2024[4] - The projected net profit attributable to the parent company for 2024 is expected to be between -335 million and -385 million CNY[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -395 million and -450 million CNY for 2024[4] Historical Performance - In 2023, the company reported an operating revenue of 357.08 million CNY and a net loss attributable to the parent company of -1.48 billion CNY[6] Business Development - The company has focused on advancing the commercialization of the meningococcal conjugate vaccine and the development of non-COVID vaccine products[7] - The company has improved its sales channels and the market share of its exclusive product, the ACYW135 meningococcal polysaccharide conjugate vaccine, is continuously increasing[7] Operational Efficiency - Management expenses and research and development expenses have decreased year-on-year, contributing to improved operational efficiency[7] - The company has optimized resource allocation and implemented cost reduction measures, leading to a significant decrease in asset impairment losses compared to the previous year[7] Earnings Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[8] - The data provided is preliminary and the final audited financial data will be disclosed in the official annual report for 2024[9]

证券代码：688185 证券简称：康希诺 公告编号：2024-051 康希诺生物股份公司 自愿披露关于ACYW135群脑膜炎球菌多糖结合疫苗 （CRM197载体）药品补充申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）的 ACYW135 群脑膜炎球菌多糖 结合疫苗（CRM197 载体）（以下简称"MCV4"）药品补充申请（以下简称"补 充申请"）于近日获得国家药品监督管理局出具的《受理通知书》，受理号： CYSB2400306。现将相关情况公告如下： MCV4 的适用人群年龄范围扩大尚需获得药品补充申请批准通知书，本次补 充申请获受理不会对公司现阶段业绩产生重大影响。 公司将对该产品的后续进展情况及时履行信息披露义务，公司信息以公司指 定披露媒体以及上海证券交易所网站刊登的公告为准。敬请广大投资者谨慎决 策，注意投资风险。 特此公告。 康希诺生物股份公司董事会 一、产品及补充申请情况 公司的 MCV4 已获得国家药品监督管理局下发的《药品注册证书》，具体情 况详见公 ...

Financial Performance - The company's revenue for Q3 2024 reached ¥263,646,520.16, representing a year-over-year increase of 76.09%[2] - Net profit attributable to shareholders for Q3 2024 was ¥2,964,467.27, while the net loss for the year-to-date period was ¥222,409,418.57, a significant reduction in loss compared to the previous year[2][5] - The company achieved a sales revenue of ¥516,153,650.93 from its meningococcal vaccine, marking a year-over-year growth of 39.07%[5] - Total operating revenue for the first three quarters of 2024 reached CNY 567,077,966.63, a significant increase from CNY 175,631,799.90 in the same period of 2023, representing a growth of approximately 223%[13] - The net loss for the first three quarters of 2024 was CNY 227,196,536.24, compared to a net loss of CNY 1,454,919,925.84 in the same period of 2023, showing an improvement of approximately 84%[14] - The company reported a comprehensive loss of CNY -226,815,781.51 for the third quarter of 2024, compared to a comprehensive loss of CNY -1,454,797,112.46 in the same quarter of 2023[15] Research and Development - Research and development (R&D) expenses totaled ¥107,918,795.43 in Q3 2024, accounting for 40.93% of revenue, a decrease of 52.89 percentage points year-over-year[3][6] - Research and development expenses for the first three quarters of 2024 were CNY 272,272,224.71, down from CNY 461,673,523.32 in 2023, reflecting a decrease of about 41%[13] - The company has focused on cost reduction and efficiency improvements, leading to a significant decrease in management and R&D expenses[5] Assets and Liabilities - The total assets of the company as of the end of Q3 2024 were ¥7,989,566,970.77, down 14.26% from the previous year[3] - Total current assets as of September 30, 2024, amounted to CNY 4,369,254,431.78, a decrease of 15.6% from CNY 5,180,827,776.61 as of December 31, 2023[10] - Total non-current assets decreased to CNY 3,620,312,538.99 from CNY 4,137,941,596.05, a decline of 12.5%[11] - Total liabilities decreased to CNY 2,926,151,613.50 from CNY 4,031,354,058.75 year-over-year, a reduction of approximately 27%[12] - Total liabilities decreased to CNY 1,172,000,000.00 from CNY 1,500,000,000.00, indicating a reduction of 21.9%[11] - The total equity attributable to shareholders of the parent company was CNY 5,063,415,357.27, down from CNY 5,274,604,094.18 in the previous year, a decline of about 4%[12] Cash Flow - The company reported a cash flow from operating activities of -¥287,414,483.35 for the year-to-date period, a decrease in net outflow of 61.63% compared to the previous year[6] - In the first three quarters of 2024, the cash inflow from operating activities was approximately CNY 609.95 million, a slight decrease from CNY 615.81 million in the same period of 2023[16] - The net cash outflow from operating activities for the first three quarters of 2024 was CNY -287.41 million, compared to CNY -748.97 million in the first three quarters of 2023, indicating an improvement[17] - Total cash outflow for operating activities in the first three quarters of 2024 was CNY 897.37 million, down from CNY 1.36 billion in 2023, indicating improved cash management[17] - The ending cash and cash equivalents balance as of the third quarter of 2024 was CNY 868.93 million, a significant decrease from CNY 2.35 billion at the end of the third quarter of 2023[18] Future Outlook - The company is focusing on new product development and market expansion strategies to enhance future growth prospects[10] - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance revenue growth and operational efficiency[12]